10 Potential Takeover Targets with Strong Price Momentum

7. Qiagen N.V. (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) is one of the 10 potential takeover targets with strong price momentum. The latest relevant development came on April 14, 2026, when QIAGEN said it was expanding into bloodstream infection syndromic testing with a new rapid QIAstat-Dx panel. The launch pushes the company into another clinically important diagnostics category and broadens the QIAstat-Dx menu beyond respiratory, gastrointestinal, and meningitis and encephalitis testing, reinforcing the strategic value of its diagnostics platform.

That helps explain why takeover interest resurfaced earlier this year. On January 20, 2026, Reuters reported that QIAGEN was weighing strategic options, including a potential sale, amid fresh takeover interest and had engaged advisers as its supervisory board considered preliminary interest from potential buyers, including several U.S. strategic firms. The market took the report seriously. Reuters said QIAGEN’s U.S.-listed shares rose more than 16% in afternoon trading on the news, giving the stock a clear takeover-driven momentum jolt.

What makes QIAGEN attractive is the combination of scale, installed diagnostics platforms, and an expanding product pipeline. In January, the company said its 2026 priorities include growth across five pillars, including syndromic testing, digital PCR, sample technologies, clinical genomics, and partnered companion diagnostics, while its investor materials highlight more than 500,000 customers and strong cash generation. No buyer has been publicly identified beyond reports of interest from possible suitors, but the combination of fresh product expansion and renewed strategic interest keeps QIAGEN firmly in the conversation.

Qiagen N.V. (NYSE:QGEN) is a molecular diagnostics and life sciences company that provides sample and assay technologies for research, clinical testing, and applied markets.